INT52460

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1995
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 2.50
Pain Relevance 0.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (SUCLA2) small molecule metabolic process (SUCLA2) ligase activity (SUCLA2)
Anatomy Link Frequency
plasma 1
SUCLA2 (Homo sapiens)
Pain Link Frequency Relevance Heat
mu opioid receptor 1 98.04 Very High Very High Very High
Bioavailability 2 96.22 Very High Very High Very High
Inflammation 6 93.12 High High
Opioid 4 92.32 High High
Pain 1 85.84 High High
cINOD 1 77.84 Quite High
tolerance 1 77.84 Quite High
adenocard 1 75.00 Quite High
peripheral neuropathy 8 72.40 Quite High
cytokine 1 25.00 Low Low
Disease Link Frequency Relevance Heat
Hypersensitivity 1 99.42 Very High Very High Very High
Stress 14 95.16 Very High Very High Very High
INFLAMMATION 7 93.12 High High
Disease 47 88.92 High High
Diabetes Mellitus 9 88.64 High High
Fever 1 86.24 High High
Pain 1 85.84 High High
Ulcers 1 83.88 Quite High
Parkinson's Disease 6 82.92 Quite High
Syndrome 6 81.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Over the past decade, a growing number of nuclear genetic defects have been identified that disrupt mitochondrial function either by a reduction in mtDNA copy number, and/or the accumulation of secondary mtDNA deletions: POLG1, POLG2, PEO1, SLC25A4, TYMP, DGUOK, TK2, SUCLA2, SUCLG1, MPV17 and RRM2B (Hudson and Chinnery, 2006; Chinnery and Zeviani, 2008; Copeland, 2008).
Localization (accumulation) of SUCLA2
1) Confidence 0.67 Published 2010 Journal Brain Section Body Doc Link PMC2842512 Disease Relevance 0.66 Pain Relevance 0.07
The aim of the present study in 12 healthy subjects was to compare the oral bioavailability of 20 mg piroxicam in a CHF1194 tablet and a plain piroxicam capsule after a single dose and after two weeks of once daily administration, and also to assess the plasma levels and urinary excretion of beta-cyclodextrin after CHF1194 administration.
Localization (excretion) of beta-cyclodextrin in plasma associated with bioavailability
2) Confidence 0.53 Published 1995 Journal Eur. J. Clin. Pharmacol. Section Abstract Doc Link 7768257 Disease Relevance 0.08 Pain Relevance 0.20
Moreover, it has been demonstrated that, in the presence of A-beta, insulin prevents the decline in mitochondrial oxidative phosphorylation efficiency and avoids an increase in oxidative stress [24].
Localization (presence) of A-beta associated with stress
3) Confidence 0.18 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2871552 Disease Relevance 1.09 Pain Relevance 0
We also measured its anti-allergic effect by its inhibition of beta-hexosamidase release.
Localization (release) of beta-hexosamidase associated with hypersensitivity
4) Confidence 0.01 Published 2008 Journal J Cosmet Sci Section Abstract Doc Link 18841306 Disease Relevance 0.60 Pain Relevance 0.21
Human beta-casomorphin-4 and soymorphin-5 were released from the soy 7S fraction (beta-conglycinin) by the action of gastrointestinal proteases.
Localization (released) of beta-conglycinin
5) Confidence 0.01 Published 2007 Journal Biosci. Biotechnol. Biochem. Section Abstract Doc Link 17928679 Disease Relevance 0.07 Pain Relevance 0.38

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox